First Patients Enrolled in Medtronic Trial in Low-Risk Aortic Stenosis Patients

Medtronic plc (NYSE: MDT) today announced that the first patients were enrolled in the expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news